Orphan disease drug developer PhaseBio Pharmaceuticals, which counts Johnson & Johnson, Astellas and AstraZeneca as investors, cut the price of its shares sharply pre-offering.

Harley-Davidson-backed electric dirt bike producer Alta Motors had raised more than $43m

The endpoint security software producer has hired Goldman Sachs for an initial public offering that would enable Alphabet, Rackspace and Telstra to exit.

Endocyte emerged out of Purdue University in 1996, completed an initial public offering in 2011 and has now agreed to an acquisition by Novartis worth $2.1bn.

Warp Drive Bio, the genomic medicine developer co-founded by Sanofi, has agreed to an all-share acquisition by Revolution Medicines.

The Relx-backed data miner could double its valuation to $41bn in the proposed offering, according to prospective underwriters.

The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.

Occupational learning tool developer NovoEd, based on research at Stanford, has been bought by Devonshire Investors after raising $4.8m of series A capital in 2014.

Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.

Banks have reportedly suggested a $120bn valuation for Uber's IPO, while Lyft has chosen JP Morgan to lead an offering that could value it at more than $15bn.